| Swiss Finance Zone |
|
Last build date |
Wed, 24 Feb 2010 02:15:58 -0700 |
| Site |
Swiss Stocks Research |
| Webmaster |
fm@methodsandtools.com |
| Category |
Whats New |
| Generator |
XOOPS WhatsNew 2.12 |
| Language |
en |
| Nestlé: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Wed, 24 Feb 2010 02:15:58 -0700 |
| Site |
In 2009, the Nestlé Group’s sales reached CHF 107.6 billion, with organic growth of 4.1%, including real internal growth of 1.9%. Foreign exchange impacted sales by -5.5% and divestitures, net of acquisitions, by -0.7%. Food and Beverag ... more... |
| Givaudan: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Fri, 19 Feb 2010 15:21:16 -0700 |
| Site |
In 2009, Givaudan group sales totalled CHF 3,959 million, an increase of 1.4% in local currencies and a decrease of 3.1% in Swiss francs compared to the previous year. On a comparable basis (in local currencies and excluding the impact of divestment ... more... |
| Swiss Re: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Fri, 19 Feb 2010 15:14:16 -0700 |
| Site |
Swiss Re returned to profit in 2009, reporting net income of CHF 506 million, compared to a loss of CHF 864 million in the prior year. Net income was impacted by impairments of CHF 2 billion, mainly in the securitised products portfolio, and by mark ... more... |
| Credit Suisse: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Fri, 12 Feb 2010 11:23:28 -0700 |
| Site |
Credit Suisse Group achieved a strong performance in 2009, with net income of CHF 6.7 billion, a return on equity of 18.3% and net new assets of CHF 44.2 billion. The tier 1 ratio was 16.3%. In 4Q09, the Group recorded net income of CHF 0.8 billion, ... more... |
| UBS: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Wed, 10 Feb 2010 23:22:15 -0700 |
| Site |
Net loss attributable to shareholders decreased to CHF 2,736 million for full-year 2009 from CHF 21,292 million in 2008. Adjusted for the items below, the underlying pre-tax profit for 2009 was CHF 1.4 billion. In 2009, the biggest negative accountin ... more... |
| Zurich Financial Services: Bordier Confirm PLUS |
| Category |
Swiss Market News
|
| Public date |
Wed, 10 Feb 2010 00:11:38 -0700 |
| Site |
The group’s Q4 and annual results for 2009 were marginally better than the already high expectations. Their quality is in fact well above average in recurring terms. As a result the group can afford the luxury of rewarding its shareholders with ... more... |
| Petroplus: Helvea Cuts Target Price To CHF20 |
| Category |
Swiss Market News
|
| Public date |
Sat, 06 Feb 2010 09:40:11 -0700 |
| Site |
Petroplus 2010 refinery market outlook has pleased Helvea, which, however, keeps its bearish longterm view on the gasoline market, cutting its price target for the Swiss-listed refiner to CHF20 from CHF24. Broker also says that Petrolplus needs to im ... more... |
| Zurich: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Sat, 06 Feb 2010 09:38:28 -0700 |
| Site |
Zurich Financial Services Group (Zurich) reported today continued strong operating performance, sustained profitability in all its core business segments and targeted growth in profitable market segments, particularly in Global Life and Farmers. For ... more... |
| Roche: Full Year Results and Analysts Reactions |
| Category |
Swiss Market News
|
| Public date |
Sat, 06 Feb 2010 09:25:16 -0700 |
| Site |
Roche reported a decline in full-year net profit on expenses related to the takeover of California-based biotech firm Genentech last year, but said brisk sales of flu drug Tamiflu and cancer medicines drove revenue higher. Sales of prescription drug ... more... |
| Morgan Stanley Ups Roche, Novartis Price Targets |
| Category |
Swiss Market News
|
| Public date |
Sun, 31 Jan 2010 14:51:00 -0700 |
| Site |
Morgan Stanley raises its Roche price target to CHF227 from CHF200 and its Novartis target to CHF61 from CHF49.50. Morgan Stanley cites Roche as one of its favored stocks in the European pharma industry and keeps an overweight rating. The bank points ... more... |
| Credit Suisse - Research |
| Category |
Swiss Stocks Links
|
| Public date |
Mon, 12 Jan 2009 23:38:07 -0700 |
| Site |
Free publication of research on the Swiss and world stock market. (registration required) more... |
